MarketPulse

weight loss drugs

16 articles
BenzingaBenzinga··Vandana Singh

India's Generic Semaglutide Flood Slashes Ozempic Costs by 70%, Reshaping Global Obesity Market

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.
NVOHIMSRDYweight loss drugsobesity market
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's April 10 FDA Decision Could Transform Weight Loss Market, But Patience Pays

Eli Lilly awaits April 10 FDA decision on oral weight loss drug orforglipron, amid $11B quarterly sales from current portfolio. Approval could catalyze gains, but long-term fundamentals matter more than short-term decisions.
LLYNVOFDA approvalGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Faces Reality Check as Valuation Reaches Peak Levels

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.
PFELLYNVOGLP-1 drugsweight loss drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Sub-$50 Healthcare Stocks Poised for Growth in Pharma, Oncology Sectors

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.
PFENVOEXELvaluationbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Market Dominance vs. Viking's Promise: Weight Loss Drug Showdown

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.
LLYNVOVKTXclinical trialsmarket share
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly Warns of Unknown Impurity in Compounded Weight Loss Drugs

Eli Lilly warns of unidentified impurity in compounded tirzepatide weight loss drugs mixed with vitamin B12, urging FDA recalls and stricter oversight.
LLYweight loss drugsZepbound
The Motley FoolThe Motley Fool··Dave Kovaleski

Major Asset Manager Exits $18M Hims & Hers Position Ahead of Novo Nordisk Reconciliation

BLKBRD Asset Management fully exits $18M Hims & Hers position in Q4 2025, just before company reconciles with Novo Nordisk.
NVDAGOOGGOOGLNVOHIMSpartnershipweight loss drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk Stock Looks Cheap, But Execution Risks Cloud Recovery Outlook

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.
LLYNVOweight loss drugspharmaceutical competition
The Motley FoolThe Motley Fool··Brett Schafer

Constellation Brands Stock Trades at Decade Lows Amid Consumption Headwinds

Constellation Brands stock falls 42% amid consumption concerns and weight loss drug competition, but maintains strong Mexican beer brands and trades at decade-low valuations.
BRK.ABRK.BSTZmarket share gainsvaluation
The Motley FoolThe Motley Fool··Rich Smith

Hims & Hers Faces Growth Deceleration as GLP-1 Market Dynamics Shift

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.
LLYNVOHIMSearnings reportGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Strengthens Market Position With Weight-Loss Drug Success

Eli Lilly strengthens market position with blockbuster weight-loss drug Zepbound, diversified pipeline, and AI integration, supporting consistent financial performance and shareholder returns.
LLYdividend growthweight loss drugs
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials